Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 7.6% – What’s Next?

Gyre Therapeutics, Inc. (NASDAQ:GYRE) traded up 7.6% during mid-day trading on Tuesday . The company traded as high as $11.45 and last traded at $11.35. 12,713 shares changed hands during trading, a decline of 84% from the average session volume of 78,660 shares. The stock had previously closed at $10.55.

Gyre Therapeutics Stock Performance

The firm’s 50 day moving average is $11.41 and its 200 day moving average is $12.33.

Insider Transactions at Gyre Therapeutics

In other Gyre Therapeutics news, President Songjiang Ma sold 2,000 shares of the business’s stock in a transaction on Thursday, December 26th. The stock was sold at an average price of $12.70, for a total value of $25,400.00. Following the sale, the president now directly owns 2,928,467 shares of the company’s stock, valued at approximately $37,191,530.90. The trade was a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 30,054 shares of company stock valued at $342,277 in the last ninety days. 19.52% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Gyre Therapeutics

Large investors have recently modified their holdings of the stock. FMR LLC bought a new stake in Gyre Therapeutics during the 3rd quarter valued at about $47,000. Wells Fargo & Company MN grew its holdings in shares of Gyre Therapeutics by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock valued at $49,000 after buying an additional 913 shares during the last quarter. Bank of America Corp DE increased its position in shares of Gyre Therapeutics by 40.4% during the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after acquiring an additional 1,996 shares in the last quarter. Barclays PLC lifted its position in Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Gyre Therapeutics by 11.1% during the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock valued at $168,000 after purchasing an additional 1,389 shares during the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.